Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03912064
Title A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

acute myeloid leukemia

myelofibrosis

myelodysplastic syndrome

chronic myelomonocytic leukemia

myelodysplastic/myeloproliferative neoplasm

Therapies

Ipilimumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.